1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Applied BioCode Corp.

Applied BioCode Corp.

TTWSE:6598
30.30
TWD
0.00
(0.00%)
-0.47EPS
2.35BMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.16
0.6
- -
0.25
0.54
0.66
1.54
3.64
3.7
4.51
4.83
3.79
4.62
6.45
Basic EPS, GAAP
-9.1
-2.82
- -
-2.94
-5.34
-4.79
-4.12
-1.26
-1.91
-2.14
-2.01
-2.88
-1.96
-0.47
Free Cash Flow per Basic Share
-4.57
-5.32
- -
-4.03
-5.19
-5.45
-4.97
-2.13
-1.94
1.43
-2.59
-2.37
-2.29
-0.9
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.07
11.22
- -
8.5
5.1
6.58
6.94
12.58
10.44
9.43
7.64
8.55
6.26
6.82
Tangible Book Value per Share
4.85
10.04
- -
7.94
4.68
6.18
6.65
12.38
10.29
9.31
7.57
8.53
6.26
6.82
Basic Weighted Avg Shares
23
25
31
46
49
56
68
82
86
87
82
91
103
103
Sales/Revenue/Turnover
27
15
- -
12
27
37
105
299
320
390
395
343
475
667
Operating Margin (%)
-313.15
-1,071.91
- -
-1,654.46
-986.13
-725.88
-262.74
-44.65
-51.55
-49.25
-47.17
-80.94
-46.89
-9.47
Depreciation Expense
5
7
- -
11
13
17
33
44
51
57
63
61
56
54
Net Income, GAAP
-208
-71
- -
-136
-263
-268
-280
-103
-165
-185
-164
-261
-201
-49
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-781.47
-468.64
- -
-1,155.41
-984.68
-727.04
-267.52
-34.61
-51.63
-47.33
-41.55
-76.02
-42.34
-7.33
Working Capital
64
247
- -
370
239
368
428
943
766
927
736
974
732
805
LT Debt
- -
- -
- -
- -
- -
- -
63
49
45
33
18
2
39
31
Total Equity
171
316
- -
428
277
433
531
1,087
903
816
661
879
643
702
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-100.51
-29.25
- -
-63.55
-74.83
-75.66
-58.14
-12.8
-16.6
-21.49
-22.23
-33.87
-26.44
-6.93

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21
20
21
LT Borrowings
- -
- -
- -
LT Finance Leases
39
36
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
103
103
Market Capitalization
2,262
2,329
2,349

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
858
947
934
Cash, Cash Equivalents & STI
570
542
557
Accounts Receivable, Net
122
201
161
Inventories
156
193
203
Total Current Liabilities
127
157
129
Payables & Accruals
- -
- -
- -
ST Debt
21
20
21
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.88%
-26.81%
Free Cash Flow
- -
-87.44%
9.46%
Net Income, GAAP
- -
19.26%
-22.85%
Sales/Revenue/Turnover
- -
11.12%
38.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82
102
75
85
343
2025
120
116
123
116
475
2026
217
210
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.77
-0.61
-0.8
-0.69
-2.88
2025
-0.35
-0.66
-0.33
-0.63
-1.96
2026
0.2
0.27
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zonh Zen Ho
Full Time Employees
43
Sector
Health technology
Industry
Medical specialties
Address
Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119 Taipei CA Taiwan KY1-1205
IPO Date
Jun 9, 2020
Website
apbiocode.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Applied BioCode Corporation (6598.TW) develops and manufactures multiplex testing platforms and diagnostic assays for infectious diseases, autoimmune disorders, and genetic analysis. The company offers the BioCode 100 MDx system, a fully automated magnetic bead-based platform supporting up to 384-plex testing per well with chemiluminescence detection; BARCODE multiplex immunoassays covering over 100 tests for respiratory viruses, gastrointestinal pathogens, transplant monitoring, and neurology markers; and molecular diagnostic kits utilizing its proprietary MDx 3000 instrument for high-throughput PCR-based detection. Products are distributed through partnerships in clinical laboratories, hospitals, and research institutions primarily in Asia, North America, and Europe. Founded in 2005 and headquartered in Santa Fe Springs, California, USA, with manufacturing and R&D facilities in Taiwan. In late 2024, Applied BioCode expanded its BARCODE Allergy panel with 44 new tests for food and inhalant allergens, enhancing its immunology portfolio; secured a strategic distribution agreement with Sequel Med Tech in Europe for MDx products; and reported record revenue growth driven by U.S. FDA clearance for additional respiratory panels amid heightened demand for multiplex diagnostics.